LONDON, UK / ACCESSWIRE / April 17, 2018 / Active-Investors.com has just released a free research report on Allergan PLC (NYSE: AGN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=AGN as the Company's latest news hit the wire. On April 13, 2018, the Dublin-based pharmaceutical Company announced that it has officially launched TrueTear®, the first and only FDA-cleared device developed to temporarily increase tear production during neurostimulation in adult patients. The neurostimulation device will be launched during the 2018 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators annual meetings being held April 13-17, 2018 in Washington, DC. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Allergan most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
TrueTear® has Helped Make Allergan a Leading Global Eye Care Company
Jag Dosanjh, Senior Vice President at US Eye Care, Allergan, stated that TrueTear® is the latest in a long line of innovations that has helped make Allergan a leading global eye care company. The Company is excited to add this drug-free, drop-free treatment option for adult patients with inadequate tear production to our current portfolio.
Jag added that for more than 70 years, Allergan has remained focused on delivering the most innovative eye care products in the industry.
Allergan Granted Marketing Authorization by the FDA for TrueTear®
On April 25, 2017, the Company was granted marketing authorization from the US Food and Drug Administration (FDA) for TrueTear™ Intranasal Tear Neurostimulator. In May 2016, Allergan announced positive results from two pivotal trials for TrueTear™ that showed an increase in tear production upon nasal neurostimulation in adults with aqueous tear deficiency.
Allergan Acquired TrueTear® Device in 2015
In July 2015, Allergan paid approximately $125 million to acquire Oculeve and TrueTear® device. The acquisition added novel, complementary dry eye development programs to Allergan's eye care research and development (R&D) programs.
About Chronic Dry Eye
Dry eye is a condition in which a person doesn't have enough quality tears to lubricate and nourish the eye. Chronic dry eye is a disease that can be caused by advanced age, contact lens wear, certain medications, eye diseases, other medical conditions, and environmental factors. Without enough tears, the film protecting the eye can break down, creating dry spots on the cornea.
TrueTear®, a handheld neurostimulation device with disposable tips that is inserted into the nasal cavity to induce the production of natural tears, is a novel and innovative approach for those patients with inadequate tear production. In two clinical trials, TrueTear® was shown to be safe and effective for temporarily increasing tear production in adult patients. TrueTear® causes the eyes to produce their own natural tears using tiny pulses of energy. The adverse effects related to TrueTear® includes nasal pain, discomfort or burning, transient electrical discomfort, nosebleed, nasal congestion, headaches, trace blood, dot heme in nostril, facial pain, sore eye, sinus pain, periorbital pain, runny nose, nasal ulcers and light-headedness.
About Allergan PLC
Founded in 1983 and headquartered in Ireland, Allergan is a global pharmaceutical company focused on developing, manufacturing, and commercializing branded pharmaceutical, device, biologic, surgical, and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Stock Performance Snapshot
April 16, 2018 - At Monday's closing bell, Allergan's stock advanced 1.27%, ending the trading session at $166.45.
Volume traded for the day: 1.79 million shares.
Stock performance in the last month - up 0.20%; and year-to-date - up 1.75%
After yesterday's close, Allergan's market cap was at $58.23 billion.
The stock has a dividend yield of 1.73%.
The stock is part of the Healthcare sector, categorized under the Drugs - Generic industry. This sector was up 0.5% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.